… , open-label extension study to provide safety and tolerability information on the long-term
use of THC-CBD, a total of 146 patients … opioid-refractory pain, THC-CBD spray was given as …

… ; and analgesic effects in the treatment of cancer-related pain … The study showed that
the long-term use of THC/CBD spray is … open-label extension study to investigate the long-term …

… goals and tolerance. Dispensaries provided records of all … with a specific THC/CBD dose.
The mean, median, and range at … in non-cancer-related pain [16], we analyzed pain and total …

… is a cannabis extract containing fixed doses of THC-CBD, THC or … , oral spray) in 43 patients
with cancer-related pain and … Most non-randomized trials were single-arm, open-label with …

… associated with long-term opioid use or pain refractory to opioid therapy. … use of THC/CBD
oromucosal spray has also been considered as treatment for non-cancer-related chronic pain …

… Up to 40% of the patients with cancer-related pain have neuropathic … A long-term observational
study conducted in Israel … (producing effective pain management with tolerable adverse …

… pain), whereas one was an open‐label trial in 174 people that … [THC], cannabidiol [CBD],
THC:CBD combinations, THC … with cancer‐related pain,272 and opioid‐related deaths in …

… its effectiveness to alleviate cancer-related pain [79]. This study was open-label with a self-…
In patients with pain due to spinal cord injury, oral THC/CBD self-administered up to 130 mg/…

… , including chronic and cancer-related pain, the nausea and … forms of short- and long-term
synaptic plasticity. In addition, … to include cannabis-based medications and explore the wide …

… for the treatment of cancer-related pain. Currently, it is in phase 3 trials for cancer … open-label
extension study of 43 patients with long-term use of the THC:CBD oromucosal spray …